Hepatic Safety of Ketamine and Esketamine for Treatment-Resistant Depression: A Real-World Cohort Study.
J Clin Psychopharmacol July 28, 2026 DOI: 10.1097/jcp.0000000000002228 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression |
| Interventions | Ketamine Esketamine |
| Topics | Depression Esketamine Ketamine |
| Key findings | The study indicates that ketamine and esketamine are associated with a low risk of hepatic injury in patients with treatment-resistant depression, supporting their hepatic safety. |
Abstract
Hepatic Safety of Ketamine and Esketamine for Treatment-Resistant Depression: A Real-World Cohort Study.